Milan API Producer Opens High-Potent API Plant
LABOCHIM SpA completes construction on multipurpose high-potent API plant in Milan.
INFA GROUP SpA, an API producer in Milan, announced on Sept. 29, 2014 that its Segrate Milan manufacturing subsidiary, LABOCHIM SpA, has completed construction on a new multipurpose high-potent API plant. The new laboratory has a capacity of up to 2.5 Kg/batch size and manufacturing capabilities ranging from 100 grams to tens of kilograms of both advanced intermediates and APIs, classified from OEB3 to OEB5.
The company believes the new plant will expand INFA’s portfolio of products and services for both the generic-drug and CDMO segments. This plant offers INFA’s customers unique flexibility and will be exclusively dedicated to therapeutic areas outside of oncology.
Source: INFA GROUP SpA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
